Monoclonal and Polyclonal Antibodies Research
Monoclonal and Polyclonal Antibodies Research is a research topic within Radiology, Nuclear Medicine and Imaging. Science Explorer counts 110k research works in it since 1950. 21.6% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the development, engineering, and applications of therapeutic antibodies, including their interaction with Fc receptors, monoclonal antibody therapy for cancer, antibody engineering techniques such as nanobodies and bispecific antibodies, the impact of glycosylation on antibody function, and antibody pharmacokinetics.
- Therapeutic Antibodies
- Fc Receptors
- Monoclonal Antibodies
- Antibody Engineering
- Immunoglobulin G
- Nanobodies
- Antibody Pharmacokinetics
- Bispecific Antibodies
- Glycosylation
- Fc? Receptors
- Research works
- 110k fractional, since 1950
- In the world top 10%
- 24k per year above
- Top-10% rate
- 21.6% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +1% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Monoclonal and Polyclonal Antibodies Research research?
By volume, the United States and China publish the most (3.4k and 1.9k works in 2022–2025).
By volume, 2022–2025
- 1 United States 3.4k works
- 2 China 1.9k works
- 3 Germany 582 works
- 4 Japan 519 works
- 5 India 509 works
- 6 United Kingdom 471 works
- 7 France 378 works
- 8 Italy 277 works
- 9 South Korea 266 works
- 10 Canada 262 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Monoclonal and Polyclonal Antibodies Research research?
By volume in 2022–2025, University of North Carolina at Chapel Hill publishes the most Monoclonal and Polyclonal Antibodies Research research, followed by The University of Texas MD Anderson Cancer Center and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 University of North Carolina at Chapel HillUnited States 65 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 48 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 40 works
- 4 Harvard UniversityUnited States 39 works
- 5 Stanford UniversityUnited States 33 works
- 6 InsermFrance 32 works
- 7 Memorial Sloan Kettering Cancer CenterUnited States 31 works
- 8 Johns Hopkins UniversityUnited States 30 works
- 9 Centre National de la Recherche ScientifiqueFrance 30 works
- 10 Peking UniversityChina 30 works
Who are the leading researchers in Monoclonal and Polyclonal Antibodies Research?
The most-cited researchers publishing on Monoclonal and Polyclonal Antibodies Research include Bert Vogelstein.
- 1 Bert Vogelstein United States 7.1k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Monoclonal and Polyclonal Antibodies Research research done?
The largest centres of Monoclonal and Polyclonal Antibodies Research research in 2022–2025 are Beijing (China), Shanghai (China), New York (United States) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Tarrytown, South San Francisco and Thousand Oaks.
Largest cities, 2022–2025
Where it is the local speciality
- TarrytownUS · 29.3 works73×
- South San FranciscoUS · 23.8 works48×
- Thousand OaksUS · 23.7 works32×
- RahwayUS · 29.4 works30×
Location quotient: how much more of its research is in Monoclonal and Polyclonal Antibodies Research than the world average.
Where is the best place to study Monoclonal and Polyclonal Antibodies Research?
Among universities, judged by research, BOKU University, Rockefeller University and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | BOKU UniversityAustria | 48.4 | 21.8% | 10.2× | 12 | -29.2% |
| 2 | Rockefeller UniversityUnited States | 47.1 | 21.3% | 23.9× | 16 | -18.4% |
| 3 | Harvard UniversityUnited States | 46.1 | 33.6% | 2.8× | 39 | -9.9% |
| 4 | ETH ZurichSwitzerland | 45.8 | 49.4% | 1.8× | 14 | +17.7% |
| 5 | University of OxfordUnited Kingdom | 45.1 | 39.2% | 1.9× | 27 | +10.4% |
| 6 | Icahn School of Medicine at Mount SinaiUnited States | 43.1 | 30.4% | 3.9× | 21 | +53.6% |
| 7 | University of Colorado Anschutz Medical CampusUnited States | 42.9 | 30.7% | 3.7× | 11 | +178.9% |
| 8 | Ajou UniversitySouth Korea | 42.4 | 24.9% | 4.9× | 10 | +185.5% |
| 9 | Vrije Universiteit BrusselBelgium | 41.9 | 32.7% | 5.0× | 14 | -22.2% |
| 10 | University of Chinese Academy of SciencesChina | 41.6 | 27.3% | 1.1× | 20 | +200.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Monoclonal and Polyclonal Antibodies Research research growing?
Output in 2018–2022 was 1% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Monoclonal and Polyclonal Antibodies Research.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.